Recurrent linezolid-resistant Enterococcus faecalis infection in a patient with pneumonia  by Yu, Zhi-jian et al.
International Journal of Infectious Diseases 30 (2015) 49–51Recurrent linezolid-resistant Enterococcus faecalis infection in a patient
with pneumonia
Zhi-jian Yu, Zhong Chen, Hang Cheng, Jin-xin Zheng, Wei-guang Pan,
Wei-zhi Yang, Qi-wen Deng *
Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infection, The Afﬁliated Shenzhen Nanshan Hospital, Guangdong Medical
College, No. 89, Taoyuan Road, Nanshan District, Shenzhen 518052, China
A R T I C L E I N F O
Article history:
Received 15 April 2014
Received in revised form 22 May 2014
Accepted 16 June 2014







S U M M A R Y
Objective: It has been reported that LZD-resistant Enterococcus in the gastrointestinal tract of mice
colonizes persistently and shows variable minimum inhibitor concentration (MIC) values. However, the
colonization characteristics of Enterococcus with LZD resistance in patients remain elusive. Here, we
report the case of a patient with recurrent pneumonia due to infection with LZD-resistant Enterococcus
faecalis strains. The colonization characteristics of the strains isolated from this patient were analyzed.
Methods: Ten E. faecalis strains were isolated from tracheal secretions obtained from the patient during
ﬁve recurrences of pneumonia over the course of 10 months. Clonal relationships were determined by
pulsed-ﬁeld gel electrophoresis (PFGE) with SmaI-macrorestricted genomic DNA. The susceptibility of
the isolates to LZD was determined by Etest in Mueller–Hinton agar.
Results: The homology of these strains was demonstrated by PFGE, suggesting that occult bacterial
colonization by LZD-resistant E. faecalis is possible as late as a year after exposure to LZD. These strains
showed variable MICs as determined by the Etest. LZD-resistant isolates contained single or double
nucleotide mutations in domain V of 23S rRNA as conﬁrmed by PCR and sequencing. The sensitivity of
the strains to vancomycin was demonstrated by broth macrodilution, and vancomycin was an effective
clinical treatment on each occasion.
Conclusions: Our results indicate that LZD-resistant E. faecalis strains may colonize persistently in vivo,
leading to recurrent infection.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Enterococcus faecalis is an opportunistic pathogen and a major
cause of both community-acquired and nosocomial infections,
including pelvic infections, endocarditis, neonatal infections,
urinary tract infections, and respiratory infections.1 The rise in
prevalence of antibiotic-resistant enterococci, including vancomy-
cin-resistant enterococci (VRE), has gained much attention in the
clinical setting. Recently an increasing number of reports of
linezolid (LZD)-resistant enterococci have emerged in the clinic.2
Although resistance has been observed in enterococci without
prior exposure to LZD, resistance is usually associated with prior
and prolonged exposure.3 LZD resistance mainly involves three* Corresponding author. Tel.: +86 775 26553111-26402; fax: +86 755 26565025.
E-mail address: qiwendeng@hotmail.com (Q.-w. Deng).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).mechanisms: mutations in the domain V region of the 23S rRNA
gene, acquisition of the ribosomal methyltransferase gene cfr, and
mutations in the rplD gene encoding the 50S ribosomal protein
L4.4,5 Genetic mutation in the central loop of the domain V region
of the ribosome is frequently used to investigate LZD resistance in
the clinical setting. E. faecalis contains four copies of rRNA operons
(rrn) on its chromosome and the level of resistance to LZD is
correlated with the number of copies of the 23S rRNA gene that are
mutated.5,6
It has been reported that LZD-resistant Enterococcus in the
gastrointestinal tract of mice colonizes persistently and shows
variable minimum inhibitor concentration (MIC) values, as well as
mutations in the domain V region of the 23S rRNA gene. However,
the characteristics of the recurrent colonization by clinically
isolated LZD-resistant Enterococcus remain elusive. In this study,
sequential strains of E. faecalis isolated from a patient with
recurrent respiratory infections were analyzed by pulsed-ﬁeld gelciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Z.-j. Yu et al. / International Journal of Infectious Diseases 30 (2015) 49–5150electrophoresis (PFGE), and the dynamics of the MIC values and
genetic mutations in the 23S rRNA V domain were investigated.
2. Materials and methods
2.1. Case report and bacterial isolates
A 52-year-old man diagnosed with acute leukemia in August
2007 and then receiving chemotherapy for many times. He was
treated with a 5-day course of LZD at a dose of 600 mg twice daily in
February 2010 for pneumonia caused by a suspected Gram-positive
bacterium; this was his ﬁrst treatment with LZD. His condition
gradually improved, with a steady decrease in C-reactive protein
(CRP) level and an improvement in physical appearance and
radiological index. During this hospitalization, diverse antibiotic
regimens were given before the use of LZD, including ceftriaxone,
piperacillin–tazobactam, and meropenem. Cultures of blood and
sputum specimens were consistently negative. The diagnosis of
pneumonia was made on the basis of the case history, radiological
ﬁndings, inﬂammation indicators, and the treatment outcome.
LZD treatment was administered on a second occasion, on
January 11, 2011, again for the treatment of pneumonia. LZD-
intermediate E. faecalis strains E1 and E2 were isolated from
tracheal secretions on January 23 and 25, 2011, respectively.
Vancomycin at a dose of 1000 mg twice daily was then used and
continued for 5 days after his CRP level had decreased, culture of
tracheal secretions had become negative, and his radiological
index had improved. A smear test of the tracheal secretions
revealed abundant neutrophils, ﬁve epithelial cells per low-power
ﬁeld, and sometimes Gram-positive cocci in chains on Gram stain.
Culture of tracheal secretions further identiﬁed the presence of E.
faecalis.
Subsequently, the patient suffered further episodes of pneu-
monia with conﬁrmed E. faecalis infection of the tracheal secretions
on another four occasions. During the ﬁve occurrences of
pneumonia with pathogens identiﬁed, 10 E. faecalis strains were
isolated from tracheal secretions. Details of the samples are listed
in Table 1.
During the ﬁrst four occurrences of pneumonia, intravenous
vancomycin was continued for 5 days after the patient became
afebrile, expectoration ended, and the sputum culture was
recurrently negative; during the ﬁnal episode on October 6,
2011, this antibiotic was continued for 7 days after the symptoms
had alleviated and radiological ﬁndings had improved. Moreover,Table 1
Genetic mutations and minimum inhibitory concentrations (MICs) of 10
Enterococcus faecalis strains in this study
Strain MIC Genetic mutations in domain V of 23SrRNA
1 2 3 4 Ratio
E1a 4 G2424U W W W 1/4
E2a 4 G2424U W W W 1/4
E3b 32 G2424U W W G2576U 2/4
E4b 32 G2424U W W G2576U 2/4
E5c 16 G2424U W W G2576U 2/4
E6c 16 G2424U W W G2576U 2/4
E7d 4 G2424U W W W 1/4
E8d 4 G2424U W W W 1/4
E9e 32 G2424U W W G2576U 2/4
E10e 16 G2424U W W G2576U 2/4
W, wild-type.
a,b,c,d,eThe ﬁve instances of pneumonia: E1 and E2 were isolated on January 23 and
25, 2011, respectively; E3 and E4 were isolated on February 11 and 12, 2011,
respectively; E5 and E6 were isolated on March 3 and 4, 2011, respectively; E7 and
E8 were isolated on March 25 and 26, 2011, respectively; E9 and E10 were isolated
on October 6 and 8, 2011, respectively.chest X-rays revealed an inﬁltrate with air bronchogram over the
left middle ﬁeld in the ﬁrst three occurrences of pneumonia and
over the right lower lung ﬁeld in the last two occurrences. Recovery
from pneumonia was conﬁrmed by computed tomography for the
last episode of Enterococcus-associated pneumonia. During this
year of recurrent Enterococcus-associated pneumonia, the patient
had stable-phase leukemia without neutropenia and did not
receive chemotherapy. During a 2-year follow-up after the last
occurrence, the patient did not suffer from pneumonia due to an E.
faecalis infection.
2.2. Antibiotic susceptibility testing and PFGE
Susceptibility of the isolates to antibiotics commonly used
against E. faecalis was measured by Etest (AB Biodisk, Solna,
Sweden) with a 0.5 McFarland standard inoculum in Mueller–
Hinton agar (bioMe´rieux, France), in accordance with the
manufacturer’s recommendations. Results suggested that the
isolates were sensitive to ampicillin and vancomycin (by disk
diffusion method). Clinical and Laboratory Standards Institute
(CLSI) criteria and the recommendations of the European
Committee on Antimicrobial Susceptibility Testing (EUCAST) were
applied to deﬁne the cut-off points for LZD. A MIC cut-off value of
2 mg/ml was assigned as sensitive, the median was 4 mg/ml, and
resistance was deﬁned as 8 mg/ml. The MICs of vancomycin were
determined by broth macrodilution as per CLSI guidelines. For
quality control purposes, the vancomycin-sensitive E. faecalis
reference strain ATCC 29212 was used. Clonal relationships were
determined by pulsed-ﬁeld gel electrophoresis (PFGE) with SmaI-
macrorestricted genomic DNA, as reported previously.5
2.3. PCR ampliﬁcation of individual 23S rRNA genes
The domain V region (bp 2254–2683) of four different copies
(rr1, rr2, rr3, and rr4) of the 23S rRNA gene was ampliﬁed
separately and sequenced from the E. faecalis isolates in accordance
with a previously reported protocol.5 Brieﬂy, genomic DNA from
E. faecalis isolates was extracted using the Lysis Buffer for
Microorganism to Direct PCR (TAKARA, Japan). Four different
copies (rr1, rr2, rr3, and rr4) of domain V of the 23S rRNA gene
were ampliﬁed separately from E. faecalis isolates using primers
reported previously.5 Subsequently, the ampliﬁed PCR products of
the four different copies (rr1, rr2, rr3, and rr4) were separated by
agarose (1%) gel electrophoresis and the individual bands were
extracted and gel puriﬁed (Qiagen, Germany). The domain V region
(bp 2254–2683) of each 23S rRNA gene was sequenced with the
primer 50- GGCGCTGGTGGGATACTACCC-30.5
3. Results
PFGE typing results demonstrated a high homology of the 10 E.
faecalis isolates (Figure 1), suggesting occult colonization by LZD-
resistant or intermediate E. faecalis in vivo. During the course of
this study, the patient was hospitalized in different wards under
strict surveillance for hospital-acquired infection and so we
concluded that the E. faecalis infections of this patient were not
hospital-acquired. Table 1 summarizes the variable MIC values and
genetic mutations in domain V of 23S rRNA of these isolates.
Certain isolates, including E1, E2, E7, and E8, showed intermediate
resistance to LZD and contained a single G2424U mutation. The
resistant isolates, including E3–E6, E9, and E10, contained double
mutations at G2424U and G2576U in this region, indicating that
LZD-resistant strains can emerge in the host even 10 months after
ﬁnal exposure to LZD. All strains showed sensitivity to vancomycin
by broth macrodilution, and the patient recovered after each
treatment with vancomycin.
Figure 1. Pulsed-ﬁeld gel electrophoresis banding pattern of 10 Enterococcus faecalis
isolates.
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LZD-resistant E. faecalis with genetic mutations in domain V of
23S rRNA often emerge in the host after exposure to LZD. Here, the
recurrent infection with LZD-resistant E. faecalis may have been
due to the repeated administration of LZD during the early phase of
pneumonia. LZD resistance is often explained by genetic mutations
in domain V of 23S rRNA when selective pressure is applied,
however it remains unclear how long the resistant strain can
colonize in vivo. In this study, the recurrent detection in tracheal
secretions of LZD-intermediate or resistant E. faecalis occurred for a
year after ﬁnal exposure to LZD and detection of the resistant
strain. Moreover, all isolates in this study showed high homology,
as demonstrated by PFGE, suggesting long-term colonization and
difﬁculty in eradicating LZD-resistant strains in vivo even after
1 year.
There are two possible explanations for the difﬁculty in
eliminating the LZD-resistant isolates in this patient. The patient
suffered from acute leukemia which would affect his ability to
recover from pneumonia. Under these conditions, even a course of
vancomycin or other antibiotics is insufﬁcient to eliminate the
LZD-resistant strains. Additionally, LZD-resistant E. faecalis is more
difﬁcult to eradicate and patients are more susceptible to recurrent
ﬂare-ups as compared to patients infected with LZD-sensitive
bacteria.7,8 Under normal conditions, the MIC of LZD-resistant E.
faecalis gradually decreases over time after exposure to LZD has
ended. In the current study, however, isolates with ﬂuctuating MIC
values were detected in the patient. We speculate that E. faecalis
colonized the host and different strains with high homologyresulted in different MIC values and genetic mutations in domain V
of the 23S rRNA gene due to LZD exposure. These colonies reside in
the respiratory tract, oropharyngeal isthmus, or other parts of the
host. These strains recurrently ﬂare up to a pathogenic state at
different times under speciﬁc conditions. We found that E. faecalis
infection in this patient could be controlled by vancomycin, and
with prolonged vancomycin treatment the infection was cleared,
suggesting that prolonged treatment may facilitate the elimination
of LZD-resistant Enterococcus.
In conclusion, our study describes the characteristics of
colonizing LZD-resistant E. faecalis in vivo and demonstrates the
importance of monitoring recurrent ﬂare-ups from infection with
this type of strain. Our ﬁndings may also help deﬁne the best
therapeutic strategies to eradicate LZD-resistant E. faecalis in the
clinical setting.
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